Lilly Makes Billions of Weight-Loss Pills
Digest more
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled to $3.57 billion in the third quarter. Meanwhile, revenue ...
Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...
In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...
Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...
The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...
Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate ...
The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were ...
CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback